Pharma Business Int

The complete guide to this fast-moving, innovative and highly specialised pharmaceutical industry.

[Pharma Business Int @PBIForum]

The latest issue of Pharma Business International is live - featuring the latest on coronavirus and how #COVID19 is impacting research in rare diseases. Plus an M&A breakdown, a look at tuberculous and much more. Read for free: https://t.co/l3E4WDgz5j

[Pharma Business Int @PBIForum]

Soleno Therapeutics secures U.S. FDA approval for VYKAT XR to treat hyperphagia in Prader-Willi syndrome https://t.co/e4vxn8QT9r

[Pharma Business Int @PBIForum]

Qfitlia approved as first therapy in US to treat hemophilia A or B with or without inhibitors https://t.co/0OPUMlPKXY

[Pharma Business Int @PBIForum]

Blujepa approved by US FDA for treatment of uncomplicated urinary tract infections https://t.co/ECJzkv7vif

[Pharma Business Int @PBIForum]

AstraZeneca to invest $2.5bn in global strategic R&D centre, biotech agreements and manufacturing in Beijing https://t.co/E8V9IObVSm

[Pharma Business Int @PBIForum]

Dupixent approved as first biologic medicine in Japan for patients with COPD https://t.co/6sAljJ0svd

[Pharma Business Int @PBIForum]

TIVDAK approved by Japan Ministry of Health, Labour and Welfare for advanced or recurrent cervical cancer that has progressed on or after chemotherapy https://t.co/Jp5EETXVl9

[Pharma Business Int @PBIForum]

Chiesi acquires new manufacturing site in Nerviano https://t.co/trYVRr2UCL

[Pharma Business Int @PBIForum]

Return on investment in pharma R&D rises with GLP-1 drugs helping drive growth https://t.co/B3YYA11Xag

[Pharma Business Int @PBIForum]

Chlamydia vaccine candidate granted US FDA fast track designation https://t.co/Oj9pP9Odjo

[Pharma Business Int @PBIForum]

Augustine Therapeutics raises €78m https://t.co/HWAINekabm

[Pharma Business Int @PBIForum]

Initiative launched to assess sustainability of digital vs. traditional clinical trial approaches https://t.co/CflbDO3rrK

[Pharma Business Int @PBIForum]

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline https://t.co/5wa517xSSp

[Pharma Business Int @PBIForum]

Cancer Research Horizons launches Cancer Impact Club with entrepreneurs and investors to raise £5m https://t.co/vVLbSMfqh2

[Pharma Business Int @PBIForum]

AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of oncology assets https://t.co/zrDoDZX2G6

[Pharma Business Int @PBIForum]

AstraZeneca to acquire EsoBiotec in $1bn deal https://t.co/TVNG9p9fqD

[Pharma Business Int @PBIForum]

SKYCLARYS approved by Health Canada for Friedreich’s ataxia https://t.co/0XBwohJIDj

[Pharma Business Int @PBIForum]

Maxion Therapeutics raises $72m in oversubscribed Series A financing to advance KnotBody pipeline and platform https://t.co/AEflaJSdUT

[Pharma Business Int @PBIForum]

Araris Biotech to be acquired by Taiho Pharmaceutical for up to $1.14bn https://t.co/os6pENdgVl

[Pharma Business Int @PBIForum]

Atsena Therapeutics granted U.S. FDA Fast Track designation for gene therapy to treat X-linked retinoschisis https://t.co/I3UXd2vd3y

[Pharma Business Int @PBIForum]

Rxulti approved in European Union for treatment of schizophrenia in adolescents aged 13 and older https://t.co/n3bqHFs0zY